EP2506857

SHIRE HUMAN GENETIC THERAPIES
Application Number
EP10835016A
Filing Date
Nov 30, 2010
Status
Revoked
May 4, 2024
Grant Date
Feb 14, 2018
External Links
Slate, Register

Biblio Summary

The patent EP2506857B1 was granted on Feb 14, 2018 by Shire Human Genetic Therapies The patent is currently Revoked.

The table below shows 2 patent oppositions filed on the patent at EPO, listing each opposing company and filing date. Tracking these filings indicates that the applicant is active in this industry, while opposing companies may be signaling their own interest in competing within the same space. These disputes are essential for insights into competitor actions, patent strategy and emerging technological trends.

CompanyOpposition DateOpposition Status

Get instant alerts for new oppositions and patent status changes

BRADY, PAUL ANDREWNov 14, 2018ADMISSIBLE
WITHERS & ROGERS LLPNov 14, 2018ADMISSIBLE

The table below shows the patents of Shire Human Genetic Therapies that have been opposed by other companies.

Patent NumberTitleGrant DateOpposition Count
EP2858679Pulmonary Delivery Of Mrna To Non-Lung Target CellsJun 5, 20241
EP3626258Methods And Compositions For Cns Delivery Of Iduronate-2-SulfataseAug 4, 20211
EP2970456Methods And Compositions For Delivering Mrna Coded AntibodiesMay 19, 20214

Dossier Documents of the Patent

The documents dossier of the patent at EPO including all essential records in the patent's lifecycle, from filing to grant to oppositions.